Risk assessment for neurobehavioral toxicity. by McMillan, D E
EnvironmentalHealthPerspectives
Vol. 76, pp. 155-161, 1987
Risk Assessment for Neurobehavioral
Toxicity
by Donald E. McMillan*
A study by the National Academy of Sciences/National Research Council (NAS/NRC) found neurobe-
havioral toxicity to be one ofthe areas where almost no data are available for the assessment oftoxicity.
Using the NAS/NRC report and a data base from the American Conference of Government Industrial
Hygienists (ACGIH), an estimate of the number of neurobehavioral toxins in commercial chemicals can
be made. Although theassumption made inmakingsuch acalculation may be invalid, theexercisesuggests
that the number of neurobehavioral toxins may be quite large. There does seem to be general agreement
as to what type of neurobehavioral test procedures are appropriate for regulatory purposes. Select com-
mittees have consistently recommended the use oftest batteries that include schedule-controlled behavior,
motor activity, and neuropathological examination following in vivo perfusion, for regulatory purposes.
Alkyltin data developed from such a battery were applied to the risk assessment model employed by the
United States Environmental Protection Agency (EPA) in their calculations of acceptable daily intake.
Using this test battery and the EPA risk assessment model, the acceptable daily intake calculated is of
the same order of magnitude as the total limit values established by the ACGIH. A number of special
issues in neurobehavioral toxicity also are discussed, including the definition of adverse neurobehavioral
toxic effects, species extrapolation, correlation ofbehavior and neuropathology, alternative methods, and
quality of life issues.
Introduction
In 1980, the National Toxicology Program commis-
sioned the National Academy of Sciences/National Re-
search Council (NAS/NRC) to estimate the number of
chemicals in the environment that produce human
health risks and to develop a priority system for the
toxicity testing ofchemicals that might present risks to
humans. In attempting to fulfill these obligations, the
NAS/NRC appointed select committees to prepare a
report (1). From various lists ofchemicals, one ofthese
committees defined a select universe of approximately
65,000 chemicals as a base for the study. A stratified,
random sample of 100 chemicals was carefully selected
to allow generalization from the sample to the select
universe. The sample included pesticides, drugs, cos-
metics, and chemicals in commerce.
In the second stage of the NAS/NRC report, the
Committee on Toxicity Data elements developed guide-
lines for determining the quality of individual toxicity
studies reported in the literature and thenreviewedthe
data base for each of the 100 chemicals in the sample
accordingtotheguidelines. Amongseveral areaswhere
data adequate for the evaluations of toxicity was fre-
quentlyunavailable wasneurobehavioraltoxicity. Table
1 shows the proportion of chemicals by chemical class
for which data adequate for the evaluation of neuro-
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Table 1. Chemicals by chemical category with neurobehavioral
toxicity data adequate for evaluation of neurobehavioral
toxicity.'
% With prescribed
minimal neurobehavioral
Chemical category toxicity data
Pesticides and pesticide ingredients 1-9
Cosmetic ingredients 0
Drugs and formulation ingredients 20-29
Food additives 10-19
Chemicals in commerce, 0
> 1 million lb/yr
Chemicals in commerce, 10-19
< 1 million lb/yr
Chemicals in commerce, 0
amount unknown
aData are from NAS/NRC (1).
behavioral toxicity were available. Clearly, there are
available few data in the literature for evaluation of
neurobehavioral toxicity for any ofthe classes ofchem-
icals.
The NAS/NRC report did not attempt to determine
what proportion of chemicals in the select universe
might produce neurobehavioral toxicity, as the report
focused only on the question of whether or not data
meetingthe test guidelines forevaluatingtoxicity were
available and not on whether neurobehavioral toxicity
tests predicted neurobehavioral toxicity for a given
chemical. Thus, no estimate can be made ofthe numberD. E. McMILLAN
of potential neurobehavioral toxins in the select uni-
verse on the basis of the NAS/NRC report.
Anger (2) has provided a data base, which when com-
bined with the NAS/NRC report may provide a rough
estimate of the potential number of neurobehavioral
toxinsinthe selectuniverse. Angerreviewed theAmer-
ican Conference of Government Industrial Hygienists
(ACGIH) threshold limit values (TLVs). Although the
ACGIH TLVs are voluntary, several agencies have
adopted them forregulatory purposes. Anger reviewed
the ACGIH documentation book to determine the basis
for the TLVs. He found that 167 of the 588 (28.4%)
chemicals for which TLVs have been set were deter-
mined all orinpartonthebasis ofdirectnervous system
effects.
If the assumption is made that Anger's analysis of
the ACGIH TLVs applies to all chemical classes, the
NAS/NRC data can be used as an estimate ofthe num-
ber of chemicals in each chemical class and that value,
when multipled by 28.4%, gives a gross estimate ofthe
number ofneurotoxic chemicals ineach class. Inmaking
this calculation, the total number of chemicals in each
category of the select universe has been used rather
than the number of chemicals without adequate neu-
robehavioral toxicity testing, since the NAS/NRC re-
port makes no estimate of the frequency of neurobe-
havioral toxicity among those chemicals that met the
guidelines for adequate neurobehavioral toxicity test-
ing. The data based on the NAS/NRC sample and An-
gers data are shown in Table 2. According to this es-
timate, the predicted number ofchemicals that produce
neurobehavioral toxicity is in excess of 18,000.
Obviously, some ofthe assumptions made in making
these calculations are not likely to be valid. For ex-
ample, the drugs that did not meet the NAS/NRC test
guidelines but have been approved by the Food and
Drug Administration and have been widely used by the
human population are unlikely to match the 28.4% level
of neurobehavioral effect that Anger found among in-
dustrial chemicals. The purpose of making the calcula-
tion was not to establish the accuracy of the estimate
of 18,000 neurobehavioral toxins, but rather to suggest
Table 2. Estimated number of neurobehavioral toxins.a
Estimated number
Number in of neurobehavioral
Chemical category category toxins
Pesticides and pesticide 3350 951
ingredients
Cosmetic ingredients 3410 968
Drugs and formulation 1815 515
ingredients
Food additives 8627 2450
Chemicals in commerce, 12680 3652
> 1 million lb/year
Chemicals in commerce, 13911 3951
< 1 million lb/year
Chemicals in commerce, 21752 6178
amount unknown
Total 65,725 18,665
aBased on NAS/NRC (1) and Anger (2).
that there may be a large number of neurobehavioral
toxins to which the human population is potentially ex-
posed.
Accepting that there is the potential of exposure to
alarge number ofneurobehavioral toxins, how does one
begin to test for neurobehavioral toxicity? There is a
perception in the toxicology community that the field of
neurobehavioral toxicitytestingis characterized byma-
jor methodological disagreements to the extent that it
is impossible to initiate testing for regulatory purposes
at this time. However, if one reviews the recommen-
dations of various panels that have been assembled to
develop protocols for neurobehavioral toxicity testing,
as is shown in Table 3, it becomes clear immediately
that certain tests have been consistently recommended
for the past decade. Although some individuals or
groups have recommended more extensive testing than
others, Table 3 shows that there is almost unanimous
agreement that screening for neurobehavioral toxicity
should involve measurements of motor activity and
schedule-controlled behavior, aswellasneuropathology
at the level of light microscopy with in vivo perfusion
of the exposed subjects.
Motor activity is a measure ofthe animal's movement
in a controlled environment. There are a large number
of devices that have been developed to detect motor
activity (3), includingphotocells, stabilimeters, field de-
tectors, and runningwheels, amongothers. Atthistime
there is no strong consensus for any particular mea-
Table 3. Tests recommended for neurobehavioral toxicity
testing.
Selected committee
NAS/NRC (19)
NAS/NRC (1)
Public Health Service
Task Force (20)
EPA (21)
Wood (18)
Recommended tests
Circadian cycle of motor activity
Schedule-controlled behavior
Unconditioned behavior (motor activity)
Conditioned behavior (schedule-
controlled behavior)
Neuropathology with in vivo perfusion
Sensory function
Motor function
Learning and memory
Performance (schedule-controlled
behavior)
Social behavior
Affective behavior
Schedule-controlled behavior
Functional observational battery
Neuropathology
Peripheral nerve function
Motor activity
Neurotoxic esterase assay
Acute-delayed neurotoxicity
(organophosphates)
Subchronic delayed neurotoxicity
(organophosphates)
Tier 1
Neuropathology
Motor activity
Schedule-controlled behavior
Functional observation battery
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surement system, as all of them appear to generate
reproducible results under standardized conditions and
the behavior measured is sensitive to disruption by tox-
icants. The automated measurement ofpatterns of mo-
tor activity in rodents has been particularly useful in
behavioral toxicology, as it allows the continuous non-
invasive measurement ofthe effects of a chemical on a
stable behavior over long time periods (4,5).
Schedule-controlled behavior is behavior controlled
by its consequences. In the usual situation inbehavioral
toxicology, a food-deprived animal is trained to press a
levertoobtainfood. Lever press responses produce food
intermittently according to a schedule ofreinforcement,
which specifies the relationship between responses and
the food availability. After a period of training, which
may require a few days to a few months depending on
the complexity of the reinforcement schedule, the be-
haviorbaseline shows lowday-to-day variability against
which to measure the effects of chemicals. This model
has been employed widely to study the effects ofdrugs
(6), as well as environmental toxicants. Like motor be-
havior, schedule-controlled respondingpermits the non-
invasive measurement of the effects of a chemical on
behavior over a long time period. It has the advantage
over motor behavior in that behavior can be controlled
and specified by the experimenter. With ingenuity,
schedule-controlled behavioral procedures can be de-
veloped to measure specific functions such as learning,
memory, sensory thresholds, etc. The major disadvan-
tage of the procedure is that the training time under
most schedules is prolonged relative to that for motor
behavior. Although few systematic studies are avail-
able, the literature suggests that motor behavior and
schedule-controlled behavior have the same order of
magnitude of sensitivity to toxic insult (7), although a
given test may be more sensitive to the effects of one
chemical than another.
Perhaps the most serious form of neurobehavioral
toxicity is produced by those chemicals that produce
morphological damage to the CNS. Measurement of
morphological changes in the CNS requires in situ per-
fusion ofthe animal and the use ofcontemporary meth-
ods ofpreparation ofthe tissue for examination by light
microscopy and preferably by electron microscopy as
well. Appropriate procedures have been discussed by
Spencer and Schaumburg (8) for assessing the location,
type, and degree ofneurotoxicity. For the neurotoxins
that have been investigated thus far in animal models,
there is a high correlation between the type ofdamage
produced in the models and the type of damage pro-
duced in humans following accidental exposure.
To illustrate how these recommended neurobehav-
ioral toxicity tests might be used in regulatory risk as-
sessment, an example will be developed. Before re-
viewing the data base to be used in risk assessment, it
is necessary to review the risk assessment model to be
used. Although a number of sophisticated models are
under development, perhaps the one most widely em-
ployed at present is that ofthe United States Environ-
mental Protection Agency (EPA) for issuing health ad-
visories (9). The EPAhas used the ideaofan acceptable
daily intake (ADI) over a lifetime using safety factors
as first suggested by Lehman and Fitzhugh (10) and
later modified by NAS (11,12).
Under this model, a no-observed-effect level
(NOEL), a no-observed-adverse effect level (NOAEL),
or a lowest observed adverse effect level (LOAEL), is
determined on the basis ofdata collected during a com-
plete review ofthe literature. The NOEL, NOAEL, or
LOAEL is then divided by a safety factor of an uncer-
tainty factor to allow for extrapolation to the human
population as shown in Table 4. The uncertainty factors
are applied in a series of steps based on a somewhat
arbitrary factor of 10. For example, the NOEL or
NOAEL is divided by 10 to account for intersubject
variability within the human population when adequate
human data are available. A second 10-fold uncertainty
factor is applied for extrapolation across species when
humandataarenotavailable. Athirduncertaintyfactor
of 10 is applied for extrapolation when less than chronic
exposure data on animals are available in the absence
ofuseful human data. A final uncertainty factor of 1 to
10 is used when the data available are from a lowest-
observed adverse effect level, rather than a NOAEL,
although in practice this factor is almost always 10.
Thus, in a case where only subehronic animal data are
available for the identification of a LOAEL, the mg/kg
exposure representing the LOAEL is divided by 10,000
(10 x 10 x 10 x 10) to develop the ADI. Whether or
not an uncertainty factor of 10 is really appropriate at
any of these stages of extrapolation has not been well
documented. Although data allowing comparisons
across species may be derived from the literature for
some chemicals, determinations as to the variability of
response across individual animals may be difficult to
retrieve from the usual types of data reported.
The class of compounds to be subjected to risk as-
sessment under this model are the alkyltins. Alkyltin
compounds have been used as stabilizers in plastics,
wood preservatives, disinfectants, pesticides, and for a
variety of other industrial applications (13). Although
many alkyltin compounds exist, the neurobehavioral
Table 4. Guidelines for the use of uncertainty factors.a
Guideline Uncertainty factor
Extrapolation from valid data on 10
prolonged ingestion by man to protect
sensitive members ofthe population
Extrapolation from valid data on 10
prolonged ingestion by animals in the
absence of similar human data to
extrapolate from the average animal to
the average man
Extrapolation from valid data on acute or 10
less prolonged ingestion by animals in
the absence ofprolonged ingestion by
man or animals to extrapolate from less
than chronic to chronic exposure
Extrapolation from a LOAEL to a 1-10
NOAEL
aData are from Ohanian and Fenner-Crisp (9).
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toxicity of triethyltin (TET) and trimethyltin (TMT)
have been studied most widely. TET produces fluid ac-
cumulation in myelin layers, resulting in a splitting of
the myelin and severe cerebral edema, while TMT pro-
duces neuronal death, particularly in the hippocampus,
but elsewhere as well (13).
Table 5 shows some representative studies indicating
effects ofTMT on motor activity. It is obvious from the
table that mice and pigeons are more sensitivethanrats
to the effects ofTMT on motor activity. Table 6 shows
representative studies for the effects ofTMT on sched-
ule-controlled responding. Pigeons and rhesus monkeys
are more sensitive to the effects of TMT than are rats
and mice. Table 7 shows representative studies forneu-
ropathological effects ofTMT. Again, mice and pigeons
appear to be more sensitive to the effects ofTMT than
rats.
On the basis of the data in Tables 5, 6, and 7, a
LOAEL of0.5 mg/kgcan be established forthe monkey
(14) and a NOAEL of 0.3 mg/kg for the pigeon (15).
Although there is a temptation to rely on primate data,
preference for a NOEL over a LOAEL suggests the
use of the pigeon data in calculation of the ADI and
leads to the following calculation:
0.3 mg/km
10 x 10 x 10 = 0.0003 mg/kg [1]
Table 5. Effects of trimethyltin on motor activity in various
species.
LOAEL or
Animal NOEL, mg/kga Effectb Reference
Rat 6(N) None (22)
5(L) 1 then 4 (23)
3(L) l (24)
3(N) None (25)
Mouse 1(L) l (26)
Pigeon 1(L) 4 (27)
a(L), LOAEL; (N), NOEL.
bIncreased activity ( T ); decreased activity (4).
Table 6. Effects of trimethyltin on schedule-controlled behavior
in various species.
LOAEL or
Animal NOEL, mg/kga Effectb Reference
Rat 6(L) T Maze errors (28)
3(N) 4 FR rate (24)
3(N) 4 FI FR rate (29)
6.6(L) DRL disrupted (30)
Mouse 1(L) 4F FR rate (31)
Pigeon 0.3(N) 4 Fl FR rate (15)
Rhesus monkey 0.5(L) I Matching (14)
errors
a(L), LOAEL; (N), NOEL.
bIncreased activity ( t ); decreased activity (4); FR, fixed ratio;
FI, fixed interval; DRL, differential reinforcement oflow rates.
If one assumes a 70 mg/kg adult human, the ADI, or
reference dose, for man is:
70 x 0.0003 = 0.021 mg/day [2]
Ifone uses the monkey data, an additional safety factor
of 10 is required to convert the LOAEL to a NOEL
which results in a lower ADI as shown below:
lx0.5 10 X 70 kg
= 0.0035 mg/kg 10 x 10 x 10 x 1 [3]
In a similar manner, on the basis of data from
McMillan and Wenger (13), one can calculate an ADI
forTET. IncontrasttoTMT, whereratswererelatively
insensitive, rats are more sensitive to TET than mice.
Pigeons are about as sensitive to TET as rats. A
NOAEL of0.3 mg/kg can be derived forthe pigeon and
a LOAEL of0.5 mg/kg for the rat, which would result
in the calculation ofADIs for TET identical to those for
TMT (e.g., 0.0035-0.021 mg/day). If one adopts the
most conservative point of view, an ADI for both of
these alkyltins would be 0.0035 mg/kg/day.
Although there have been a few human exposures to
alkyltins, it is difficult to determine the dose to which
they were exposed. The only reference point in the lit-
erature comes from the ACGIH air standard, where
"organic compounds as tin" (16) have a TLV of0.1 mg/
m3 (based on 8 hr exposure 5 days per week). In order
to compare the ADI determined from neurobehavioral
toxicity testing with the ACGIH total limit value, it is
necessary to conivert this air quality standard to a mil-
ligram per kilogram dose absorbed. To make this con-
version involves a number of assumptions of dubious
Table 7. Neuropathology of trimethyltin in various species.
LOAEL or
Animal NOEL, mg/kga Area of effect Reference
Rat 8(L) Hippocampus (32)
7.5(L) Hippocampus (33)
5(L) Hippocampus (34)
7(L) Brainstem, spinal (35,36)
cord
6(L) Peripheral nerve (37)
(chronic neonate)
1(L) (38)
Mouse 1(N) None (23,28)
3(L) Hippocampus, (39,40)
spinal cord
Pigeon 0.3(N) None (15)
Marmoset 3(L) Hippocampus (41)
a(L), LOAEL; (N), NOEL.
validity, although it is a type of conversion sometimes
made by regulatory agencies when it is necessary to
develop a water quality standard with only air quality
data available. Assuming 7 days a week exposure,
Equation 4 can be used to make the calculation.
mg/m3 x 8 hr in m3 x week exposure x absorbed = mg/kg/day
RnIvu waiht=g/
[4]
Unfortunately, data on pulmonary absorption per-
centages are not available for alkyltins. For purposes
of making the calculation, an untested assumption of
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30% absorption of an inhaled dose was made. The cal-
culation is as follows:
0.1 m3 x 13.8 m3 x 5/7 x 0.3 * 70 ~~~~~= 0.0042 mg/kg/day [5] 70
It can be seen that the ADI calculated from the con-
version of the ACGIH total limit value is of the same
order of magnitude as that developed from the animal
model (e.g., 0.0042 versus 0.0035). Obviously these are
crude estimates with many problems in addition to the
conversion ofinhalation data to parenteral administra-
tion effects to calculate an ADI. For example, the AC-
GIH total limit value does not mention the specific al-
kyltin, and it is well known that there is wide variation
in toxicity among alkyltins (17). Furthermore, the an-
imal data are derived from doses calculated as the salts,
whereas the total limit value appears to refer only to
the tin molecule, although this point is not absolutely
clear. Nevertheless, it is interestingto note howclosely
theneurobehavioralADI matchesthatderived fromthe
ACGIH data.
At this time, comprehensive reviews ofneurobehav-
ioral toxicity data bases have not been done, so it is
unclear as to what extent neurobehavioral ADIs relate
to current regulatory standards, or perhaps the thesis
should be stated another way to say that it is unclear
to what extent neurobehavioral testresults might mod-
ify current standards. At any rate, there is a consensus
supportthatatleastsomeneurobehavioraltestmethods
are ready to be added to current test batteries for reg-
ulatory purposes.
The remainder ofthis paperwillbe devotedto ashort
discussion ofsome oftheimportant questions facingthe
field of neurobehavioral toxicity today. Some of these
questions are common in other areas oftoxicity testing,
while others are especially applicable to neurobehav-
ioral toxicity testing.
Special Issues in Neurobehavioral
Toxicity Testing
How Does One Define an Adverse
Behavioral Effect?
Cancer is an adverse effect by definition. There are
few who would argue that a malignant tumor is bene-
ficial. With chemically induced behavioral changes, the
case is less clear. For example, is an increase in motor
activity an adverse effect? Does an increase in the rate
of lever pressing, which in some cases may result in a
hungryanimalearningmorefoodinlesstime, represent
an adverse effect? Does increased accuracy in adelayed
matching-to-sample task (frequently considered to be a
measure of short-term memory) represent an adverse
effect? Until a clearbasis develops forconsidering some
chemically induced behavioral changes as adverse and
others not adverse, it would seem prudent to consider
all behavioral changes caused by chemicals as adverse
effects. If this viewpoint is adopted, the common pro-
gression from NOEL to NOAEL to LOAEL is inap-
propriate because the concept of a NOAEL is not em-
ployed. Forthisreason onlyNOELsand LOAELswere
used in Tables 5, 6, and 7. This argument is easily de-
fendedwhen achemicalproduces neuropathology, since
most neuropathologists would agree that lesions are by
definition adverse effects, butthe issue canbereopened
ifthe lesions do not produce measurable functional con-
sequence.
Why Do Chemicals Produce
Neurobehavioral Toxicity That Differs
Across Species?
Differences in neurobehavioral responses to chemi-
cals in different species appears in most instances to be
quantitativeratherthanqualitative. Itseemslikelythat
most, ifnot all, such species differences will be related
to pharmacokinetic factors rather than to fundamental
differences in structure and function ofthe nervous sys-
tem. Unfortunately, neither the pharmacokinetic nor
the neurobehavioral data are sufficiently available to
make a reasonable test ofthis assumption. Correlations
between dose-time-response data for neurobehavioral
changes with the uptake, distribution, metabolism, and
excretion oftoxic chemicals are badly needed.
Must Chemicals Act Directly on the CNS
to Produce Behavioral Toxicity?
It is obvious that some chemicals can produce pro-
found behavioral changes without ever reaching the
brain. For example, some chemicals stimulate nerve
endings of fibers that transmit pain sensation to the
brain. Although such chemicals are active in behavioral
tests, they are not neurobehavioral toxins in the usual
sense. In order for a chemical to produce peripheral
effects of sufficient magnitude to activate the CNS in-
directly and result in behavioral changes, considerable
peripheral activity must occur. Whether such periph-
eral effects are more easily and reliably directly meas-
ured than are the behavioral changes they may produce
is an unanswered question. It may be that behavioral
changes can function as a noninvasive measure of the
general well being ofthe organism.
Is There a Correlation Between CNS
Damage and Behavioral Change?
Considerable energy has been expended by neuro-
pathologists and behavioral toxicologists arguing about
whether one method is more or less sensitive than the
other. Although the answer to the question may have
some regulatory significance, it probably has little sci-
entific importance. One point should be remembered. A
large number of chemicals that produce profound be-
havioral toxicity produce no apparent lasting morphol-
ogical damage. Carbon monoxide, many psychoactive
drugs, perhaps even lead, fit into this category. Until
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a larger data base is developed, it seems appropriate to
recommend bothbehavioraltestingand neuropathology
testingwhenweknowlittle aboutthetoxicityofachem-
ical.
Alternative Methods and Animal Rights
CertaintypesoftoxicitytestingsuchastheLD50have
come under considerable criticism, especially from an-
imal rights groups, in part because such large numbers
ofanimals have been used. A major advantage ofcare-
fully controlled behavioral experiments is that they re-
duce the number ofanimals required fortoxicitytesting
to aminimum. Rigid experimental control issubstituted
for the statistical control necessary with large groups.
Whatmaybelostinthis approachistheabilitytodetect
effects that occur infrequently in large populations, if
in fact neurobehavioral toxicity occurs in this manner.
At this point in time it seems impossible to eliminate
theneed forthe useofwholeanimals inneurobehavioral
toxicity testing. Although tissue culture techniques
have shown some utility in neurotoxicity testing, the
likelihoodthatasimple systemofthistype could predict
all of the subtlety of behavior is unlikely. The whole
organism modifies its behavior as a function of its ex-
perience (learns) and acts appropriately when faced
with situations to which it has been previously exposed
(remembers). That these and other complex behavioral
processes could be modeled in tissue culture or in com-
puter program in the near future is difficult to imagine.
This does not mean that such research attempts should
not proceed, but even when promising data from these
attempts accumulate, they will have to be validated in
the whole organism.
Another alternative method is measurement at the
physiological level. For example, some chemicals re-
lease neurotransmitters, activate orblockreceptors, or
directly change nerve cell permeability while the chem-
icalis present atthetarget site. Yet, as these chemicals
are metabolized and/or excreted, these functional ef-
fects disappear. Such functional changes may produce
behavioral changes, or at least be precursors ofbehav-
ioral change; yet, until recently, such effects could not
be measured noninvasively. With some ofthe new im-
aging techniques available, such as nuclear magnetic
resonance, the situation maybechangingand functional
changes in the activity ofthe nervous system are likely
to be accessible in the near future. This is clearly a
growth area in neurobehavioral toxicity for the next
decade.
Quality of Life
Wood (18) has recently raised the issue ofquality of
life as aneurobehavioral toxicity concern. Forexample,
certain chemicals may not damage the CNS or produce
obvious behavioral deficits, yet they cause us to change
our lives to avoid exposure to the chemical. Perhaps a
good example ofthis nebulous concept is to considerthe
matter of odor. People do not remain in environments
where there are bad odors unless other factors leave
them little choice. Ifsomeone sells a home at afinancial
loss because ofits proximity to a paper mill that emits
an offensive odor, the chemical producing the odor has
caused an important behavioral change, even though it
is not neurobehaviorally toxic in the usual sense ofthe
word. Quality of life is a particularly difficult issue for
risk assessment, especially when only animal data are
available, yet it is an area where neurobehavioral toxi-
cologists need to begin to direct their attention.
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